Literature DB >> 32633164

Clinical and Mutation Description of the First Iranian Cohort of Infantile Inflammatory Bowel Disease: The Iranian Primary Immunodeficiency Registry (IPIDR).

Farzaneh Rahmani1,2,3, Elham Rayzan4,5, Mohammad Reza Rahmani6, Sepideh Shahkarami7, Samaneh Zoghi8, Arezoo Rezaei5, Zahra Aryan5, Mehri Najafi9, Meino Rohlfs10, Tim Jeske10, Majid Aflatoonian11, Zahra Chavoshzadeh12, Fatemeh Farahmand9, Farzaneh Motamed9, Pejman Rohani13, Hossein Alimadadi9, Alireza Mahdaviani14, Mahboubeh Mansouri15, Marzieh Tavakol16, Mirjam Vanderberg17, Daniel Kotlarz10, Christoph Klein10, Nima Rezaei5,18,19.   

Abstract

We describe a cohort of 25 Iranian patients with infantile inflammatory bowel disease (IBD), 14 (56%) of whom had monogenic defects. After proper screening, patients were referred for whole exome sequencing (WES). Four patients had missense mutations in the IL10 RA, and one had a large deletion in the IL10 RB. Four patients had mutations in genes implicated in host:microbiome homeostasis, including TTC7A deficiency, and two patients with novel mutations in the TTC37 and NOX1. We found a novel homozygous mutation in the SRP54 in a deceased patient and the heterozygous variant in his sibling with a milder phenotype. Three patients had combined immunodeficiency: one with ZAP-70 deficiency (T+B+NK-), and two with atypical SCID due to mutations in RAG1 and LIG4. One patient had a G6PC3 mutation without neutropenia. Eleven of the 14 patients with monogenic defects were results of consanguinity and only 4 of them were alive to this date.

Entities:  

Keywords:  G6Pc3; IL-10 Receptor; SRP54; TTC37; Very-early-onset inflammatory bowel disease; whole Exome Sequencing

Year:  2020        PMID: 32633164     DOI: 10.1080/08820139.2020.1776725

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  1 in total

1.  The clinical, molecular, and therapeutic features of patients with IL10/IL10R deficiency: a systematic review.

Authors:  Niusha Sharifinejad; Majid Zaki-Dizaji; Roya Sepahvandi; Farimah Fayyaz; Maria Marluce Dos Santos Vilela; Gehad ElGhazali; Hassan Abolhassani; Hans D Ochs; Gholamreza Azizi
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.